These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 34485908)

  • 61. Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo.
    Chien W; Lee DH; Zheng Y; Wuensche P; Alvarez R; Wen DL; Aribi AM; Thean SM; Doan NB; Said JW; Koeffler HP
    Mol Carcinog; 2014 Sep; 53(9):722-35. PubMed ID: 23475695
    [TBL] [Abstract][Full Text] [Related]  

  • 62. ERβ inhibits cyclin dependent kinases 1 and 7 in triple negative breast cancer.
    Reese JM; Bruinsma ES; Monroe DG; Negron V; Suman VJ; Ingle JN; Goetz MP; Hawse JR
    Oncotarget; 2017 Nov; 8(57):96506-96521. PubMed ID: 29228549
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Molecular mechanisms underlying the clinical efficacy of panobinostat involve Stochasticity of epigenetic signaling, sensitization to anticancer drugs, and induction of cellular cell death related to cellular stresses.
    El Omari N; Bakrim S; Khalid A; Abdalla AN; Almalki WH; Lee LH; Ardianto C; Ming LC; Bouyahya A
    Biomed Pharmacother; 2023 Aug; 164():114886. PubMed ID: 37224752
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Estrogen receptor β inhibits breast cancer cells migration and invasion through CLDN6-mediated autophagy.
    Song P; Li Y; Dong Y; Liang Y; Qu H; Qi D; Lu Y; Jin X; Guo Y; Jia Y; Wang X; Xu W; Quan C
    J Exp Clin Cancer Res; 2019 Aug; 38(1):354. PubMed ID: 31412908
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Toosendanin Exerts an Anti-Cancer Effect in Glioblastoma by Inducing Estrogen Receptor β- and p53-Mediated Apoptosis.
    Cao L; Qu D; Wang H; Zhang S; Jia C; Shi Z; Wang Z; Zhang J; Ma J
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27869737
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Interplay of m
    Li F; Chen S; Yu J; Gao Z; Sun Z; Yi Y; Long T; Zhang C; Li Y; Pan Y; Qin C; Long W; Liu Q; Zhao W
    Clin Transl Med; 2021 Sep; 11(9):e553. PubMed ID: 34586728
    [TBL] [Abstract][Full Text] [Related]  

  • 67. KDELR2 promotes breast cancer proliferation via HDAC3-mediated cell cycle progression.
    Wei H; Ma W; Lu X; Liu H; Lin K; Wang Y; Ye Z; Sun L; Huang Z; Pan T; Zhou Z; Cheng EY; Zhang H; Gao P; Zhong X
    Cancer Commun (Lond); 2021 Sep; 41(9):904-920. PubMed ID: 34146461
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi.
    Suraweera A; O'Byrne KJ; Richard DJ
    Front Oncol; 2018; 8():92. PubMed ID: 29651407
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
    Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A
    PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naïve diffuse midline glioma models.
    Vitanza NA; Biery MC; Myers C; Ferguson E; Zheng Y; Girard EJ; Przystal JM; Park G; Noll A; Pakiam F; Winter CA; Morris SM; Sarthy J; Cole BL; Leary SES; Crane C; Lieberman NAP; Mueller S; Nazarian J; Gottardo R; Brusniak MY; Mhyre AJ; Olson JM
    Neuro Oncol; 2021 Mar; 23(3):376-386. PubMed ID: 33130903
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells.
    Yang M; Wang J; Wang L; Shen C; Su B; Qi M; Hu J; Gao W; Tan W; Han B
    Prostate; 2015 Sep; 75(13):1363-75. PubMed ID: 26015225
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.
    LaBonte MJ; Wilson PM; Fazzone W; Russell J; Louie SG; El-Khoueiry A; Lenz HJ; Ladner RD
    Cancer Res; 2011 May; 71(10):3635-48. PubMed ID: 21464044
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The mTOR inhibitor everolimus overcomes CXCR4-mediated resistance to histone deacetylase inhibitor panobinostat through inhibition of p21 and mitotic regulators.
    Beider K; Bitner H; Voevoda-Dimenshtein V; Rosenberg E; Sirovsky Y; Magen H; Canaani J; Ostrovsky O; Shilo N; Shimoni A; Abraham M; Weiss L; Milyavsky M; Peled A; Nagler A
    Biochem Pharmacol; 2019 Oct; 168():412-428. PubMed ID: 31325448
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The Safety, Efficacy and Therapeutic Potential of Histone Deacetylase Inhibitors with Special Reference to Panobinostat in Gastrointestinal Tumors: A Review of Preclinical and Clinical Studies.
    Singh A; Patel P; Jageshwar ; Patel VK; Jain DK; Kamal M; Rajak H
    Curr Cancer Drug Targets; 2018; 18(8):720-736. PubMed ID: 28669336
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Enhancing progestin therapy via HDAC inhibitors in endometrial cancer.
    Li Y; Zhou W; Li L; Li JW; Li T; Huang C; Lazaro-Camp VJ; Kavlashvili T; Zhang Y; Reyes H; Li Y; Dai D; Zhu W; Meng X; Leslie KK; Yang S
    Am J Cancer Res; 2022; 12(11):5029-5048. PubMed ID: 36504895
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Preclinical Studies Support Combined Inhibition of BET Family Proteins and Histone Deacetylases as Epigenetic Therapy for Cutaneous T-Cell Lymphoma.
    Zhao L; Okhovat JP; Hong EK; Kim YH; Wood GS
    Neoplasia; 2019 Jan; 21(1):82-92. PubMed ID: 30529073
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Panobinostat reverses HepaCAM gene expression and suppresses proliferation by increasing histone acetylation in prostate cancer.
    Chen E; Liu N; Zhao Y; Tang M; Ou L; Wu X; Luo C
    Gene; 2022 Jan; 808():145977. PubMed ID: 34592353
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Comprehensive analysis of PSMD family members and validation of PSMD9 as a potential therapeutic target in human glioblastoma.
    Li Y; Liu X; Zhao F; Zhao Z; Li X; Wang J; Huang B; Chen A
    CNS Neurosci Ther; 2024 Feb; 30(2):e14366. PubMed ID: 37485655
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma.
    Singh MM; Johnson B; Venkatarayan A; Flores ER; Zhang J; Su X; Barton M; Lang F; Chandra J
    Neuro Oncol; 2015 Nov; 17(11):1463-73. PubMed ID: 25795306
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Genome-wide estrogen receptor β chromatin binding in human colon cancer cells reveals its tumor suppressor activity.
    Indukuri R; Jafferali MH; Song D; Damdimopoulos A; Hases L; Zhao C; Archer A; Williams C
    Int J Cancer; 2021 Aug; 149(3):692-706. PubMed ID: 33754337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.